In addition, iguratimod can also inhibit the IL-17 signaling pathway in RA-FLS, which is manifested in the inhibition of the release of various inflammatory cytokines triggered by IL-17 in RA-FLS, such as CCL2, CXCL1, CXCL2, IL-6 and TNF. Here, CCL2 is linked to rheumatoid arthritis.